Quest for the right Drug

|
עמוד הבית / אורסופאלק 500 / מידע מעלון לרופא

אורסופאלק 500 URSOFALK 500 (URSODEOXYCHOLIC ACID)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות מצופות פילם : FILM COATED TABLETS

Interactions : אינטראקציות

4.5   Interactions with other medicinal products and other forms of interaction

Ursofalk 500mg tablets should not be administered concomitantly with colestyramine, colestipol or antacids containing aluminium hydroxide and/or smectite (aluminium oxide), because these preparations bind ursodeoxycholic acid in the intestine and thereby inhibit its absorption and efficacy. Should the use of a preparation containing one of these substances be necessary, it must be taken at least 2 hours before or after Ursofalk 500mg tablets.

Ursofalk 500mg tablets can affect the absorption of ciclosporin from the intestine. In patients receiving ciclosporin treatment, blood concentrations of this substance should therefore be checked by the physician and the ciclosporin dose adjusted if necessary.

In isolated cases, Ursofalk 500mg tablets can reduce the absorption of ciprofloxacin.

In a clinical study in healthy volunteers concomitant use of UDCA (500 mg/day) and rosuvastatin (20 mg/day) resulted in slightly elevated plasma levels of rosuvastatin. The clinical relevance of this interaction also with regard to other statins is unknown.

Ursodeoxycholic acid has been shown to reduce peak plasma concentrations (Cmax) and area under the curve (AUC) of the calcium antagonist nitrendipine in healthy volunteers. Close monitoring of the outcome of concurrent use of nitrendipine and UDCA is recommended. An increase of the dose of nitrendipine may be necessary.

An interaction with a reduction of the therapeutic effects of dapsone was also reported.

These observations, together with in-vitro findings could indicate a potential for ursodeoxycholic acid to induce cytochrome P450 3A enzymes. Induction has, however, not been observed in a well-designed interaction study with budesonide, which is a known cytochrome P450 3A substrate.

Oestrogenic hormones and blood cholesterol lowering agents, such as clofibrate, increase hepatic cholesterol secretion and may therefore encourage biliary lithiasis, which is a counter-effect to UDCA in some cases.

שימוש לפי פנקס קופ''ח כללית 1994 Dissolution or reduction of size of radiolucent cholesterol gallstones in patients with a functioning gallbladder
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

RAFA LABORATORIES LTD

רישום

150 68 33832 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

25.02.16 - עלון לרופא

עלון מידע לצרכן

10.03.16 - עלון לצרכן אנגלית 10.03.16 - עלון לצרכן עברית 10.03.16 - עלון לצרכן ערבית 09.02.16 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אורסופאלק 500

קישורים נוספים

RxList WebMD Drugs.com